This Advanced master’s degree is an incredible opportunity to obtain in a single educational path, each and every one of the competences necessary to develop a totally updated intervention in Thoracic Oncology and Cardio-Oncologyy of total quality”

Today, to speak of oncology is to speak of multidisciplinary teams. Not losing this multidisciplinary vision is very important because many advances in one area can have implications in the diagnostic and therapeutic algorithms used in oncology. In fact, one of the skills that we aim for students to achieve with this Advanced master’s degree is to have a broad and clear vision of oncology, and to use the comparison of scientific advances in each area as a tool that will allow them to advance their knowledge. 

We could give many examples, but for the sake of brevity we would just like to point out what immunotherapy has been and will be in the management of cancer. Apart from the results of interleukin-2 in melanoma and, to a lesser extent, in renal cancer, it was a therapy on its way to extinction, with little practical use in the management of patients. Since the approval of ipilimumab for the treatment of malignant melanoma, no more than 4 years ago, the development of immunotherapy in multiple tumors, and in particular in lung cancer, has increased and is already one of the most promising lines of research. 

This Advanced master’s degree will allow the professional to acquire knowledge that will be extremely useful in daily work, based on critical work, a simple presentation and an effective methodology. We assume that simplicity is not incompatible with thoroughness, and through the acquisition of key knowledge, a critical spirit will emerge that will help to put this knowledge into practice. To this end, we offer you a cast of professors who are in the "first division" in the management of cancer, and many "international leaders", who have prepared in "depth each topic" from their vision as "super-specialists" but always bearing in mind that the ultimate goal of the Advanced master’s degree is that the knowledge can be acquired by any physician interested in thoracic and cardiological cancers. 

Another aspect of the work of this specialization will focus on helping to increase personal potential, improve clinical decision making or the implementation of personalized oncology, thanks to collaboration and networking. 
The Professional Master's Degree will have two main axes around which all its modules will revolve: Research and clinical application. All sections will be approached from the perspective of the most recent research findings. From the research point of view, both basic and clinical research lines will be addressed. The research background of the directors and co-directors of the Master's Degree will be reflected in all the modules. As this is a master's degree with a clinical application vocation, all modules will be introduced, and their content will be applied to real clinical cases". 

An Advanced master’s degree developed to provide a broad and up-to-date response to the needs of professionals in this area of intervention. The largest compendium of high quality scientific knowledge in the online teaching market”

This Advanced master’s degree in Thoracic Oncology and Cardio-Oncology contains the most complete and up-to-date scientific program on the market. The most important features include:

• Clinical cases presented by experts in the different specialties
• Graphic, schematic, and practical contents with the latest scientific and healthcare information
• Diagnostic and Therapeutic Developments in Gynecology and Assisted Reproduction  
• Practical workshops on procedures, diagnosis and treatment techniques
• Real images in high resolution and practical exercises where the self-evaluation process can be carried out to improve learning
• Algorithm-based interactive learning system for decision-making in the presented clinical situations
• Special emphasis on test-based medicine and research methodologies
• Theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Content that is accessible from any fixed or portable device with an Internet connection

This Two Year TECH Master’s Degree is the best investment that you could make into your future. A specialization created to be compatible with your professional and personal life that will take you to your goal in the easiest way, optimizing your time and effort"

Its teaching staff is made up of leading professionals in the sector. Practicing professionals who bring their experience to this training program, as well as renowned specialists from leading scientific societies.  An impressive cast of super-specialists who will put their experience and professionalism at the service of this specialization. 

Thanks to its multimedia content developed with the latest educational technology, it will allow the professional a situated and contextual learning, that is to say, a simulated environment that will provide an immersive learning programmed to prepare in real situations.  

This program is designed around Problem-Based Learning, whereby the physician must try to solve the different professional practice situations that arise during the course. For this purpose, the physician will be assisted by an innovative interactive video system created by renowned and experienced experts in the field with extensive teaching experience.

This Two Year TECH Master’s Degree is the best investment that you could make into your future. A specialization created to be compatible with your professional and personal life that will take you to your goal in the easiest way, optimizing your time and effort"

Its contents, developed entirely by the best professionals in the sector, will allow you to assimilate the lessons learned through their experience, with the incomparable possibility of having real examples and therapeutic situations"

The structure of this Master's Degree has been created in order to compile each and every one of the subjects that professionals in this area ought to master, in a comprehensive but very specific syllabus. With an extensive course, structured in areas of intervention, the student will learn the different theoretical and practical approaches and techniques necessary for medical activity in Thoracic Oncology and Cardio-Oncology. Learning that will translate into practical mastery of the techniques. Always with the tutoring and accompaniment of the exceptional teachers who have developed the contents.  

This Advanced master’s degree is an incomparable opportunity to obtain, in a single program, all the knowledge required in Thoracic Oncology and Cardio-Oncology"

Cardio-oncology Area

Module 1. Epidemiology of Cancer

1.1. Epidemiological Significance of Cancer
1.2. Epidemiological Significance of Cardiotoxicity in Oncology
1.3. Epidemiological Significance of Cardiotoxicity in Hematology

Module 2. Oncologic Treatments with Cardiotoxic Effect

2.1. Definition of Cardiotoxicity. Affected Cardiac Chambers. Pathophysiological Mechanisms of Cardiotoxicity
2.2. Radiotherapy as a Cause of Cardiotoxicity

2.2.1. Evolution of Radiotherapy Equipment and Methods
2.2.2. Factors that Influence Radiation-Induced Cardiotoxicity
2.2.3. Acute Toxicity
2.2.4. Chronic Toxicity

2.3. Chemotherapy as a Cause of Cardiotoxicity

2.3.1. Anthracyclines
2.3.2. Antitubulin Drugs
2.3.3. Antimetabolites
2.3.4. Alkylating Agents and Other Drugs that Interact with DNA

2.4. Biological Agents as a Cause of Cardiotoxicity: Monoclonal Antibodies

2.4.1. Trastuzumab
2.4.2. Other Monoclonal Antibodies

2.5. Other Potentially Cardiotoxic Biological Agents

2.5.1. Cytokines
2.5.2. Interferons

2.6. Therapies Aimed at New Molecular Targets and Cardiotoxicity: Inhibitors of Cellular Kinases
2.7. Immune Checkpoint Inhibitors and Cardiotoxicity
2.8. Other Potentially Cardiotoxic Oncologic Treatments

2.8.1. Histone Deacetylase Inhibitors
2.8.2. Oral Antiangiogenics
2.8.3. Differentiation and/or Apoptosis Inducers
2.8.4. Hormonal Agents

Module 3. Comprehensive Assessment of the Risk of Cardiotoxicity Development

3.1. Individual Susceptibility to Cardiotoxicity: Genetic Factors
3.2. Individual Susceptibility to Cardiotoxicity: Non-Genetic Factors

3.2.1. Cardiovascular Risk Factors
3.2.2. Comorbidities
3.2.3. Combination of Oncologic Treatments

3.3. Cardiological Assessment before Treatment in Patients without Known Heart Disease

3.3.1. Clinical Assessment
3.3.2. Complementary Tests

3.4. Cardiological Assessment before Treatment in Patients with Known Heart Disease

3.4.1. Clinical Assessment
3.4.2. Complementary Tests

3.5. Monitoring during Treatment of Patients Subjected to Cardiotoxic Treatments

3.5.1. Clinical Assessment
3.5.2. Complementary Tests

Module 4. Early Detection of Cardiotoxicity

4.1. Circulating Biomarkers: Troponins
4.2. Circulating Biomarkers: Natriuretic Peptides
4.3. Other Circulating Biomarkers for Early Detection of Cardiotoxicity
4.4. Echocardiography
4.5. Cardiovascular Magnetic Resonance Imaging
4.6. Computerised Axial Tomography

Module 5. Myocardial Toxicity

5.1. Incidence and Clinical Relevance
5.2. Pathophysiology of Ventricular Dysfunction and Heart Failure in the Context of Cardiotoxicity
5.3. Drugs Implicated in the Development of Ventricular Dysfunction and Heart Failure

5.3.1. Anthracyclines
5.3.2. Other Chemotherapy Drugs
5.3.3. Biological Agents: Monoclonal Antibodies
5.3.4. Therapies Aimed at New Molecular Targets: Inhibitors of Cellular Kinases
5.3.5. Proteosome Inhibitors

5.4. Radiotherapy and Heart Failure
5.5. Methods for Diagnosing Myocardial Involvement

5.5.1. Electrocardiogram
5.5.2. Echocardiography
5.5.3. Other Non-Invasive Imaging Techniques

5.6. Treatment Strategies

5.6.1. Treatment of Acute Heart Failure
5.6.2. Chronic Treatment of Patients with Ventricular Dysfunction

5.7. Presymptomatic Myocardial Involvement

5.7.1. Management of Patients with Elevated Circulating Biomarkers during Oncologic Treatment
5.7.2. Management of Patients with Preclinical Impairment of Ventricular Function during Oncologic Treatment

5.8. Monitoring Strategy during Treatment with Drugs Capable of Causing Myocardial Toxicity

5.8.1. Anthracyclines
5.8.2. Biological Agents: Monoclonal Antibodies
5.8.3. Therapies Aimed at New Molecular Targets: Inhibitors of Cellular Kinases
5.8.4. Immune Checkpoint Inhibitors

Module 6. Ischemic Heart Disease and Cardiotoxicity

6.1. Incidence of Ischemic Heart Disease in Oncology Patients
6.2. Identifying Patients at High Risk of Coronary Artery Disease
6.3. Pathophysiology of Ischemic Heart Disease in the Context of Oncologic Treatment
6.4. Pharmacologic Oncologic Therapies that are Associated with Ischemic Heart Disease

6.4.1. Fluoropyrimidine
6.4.2. Vascular Endothelial Growth Factor Inhibitors
6.4.3. Others (Cisplatin)

6.5. Diagnostic Methods for Coronary Artery Disease Related to Cardiotoxic Drugs

6.5.1. Electrocardiogram
6.5.2. Functional Tests
6.5.3. Non-Invasive Imaging Tests
6.5.4. Invasive Imaging Tests

6.6. Acute Coronary Syndrome in the Context of Oncologic Treatment
6.7. Monitoring and Treatment Strategy in the Patient with Coronary Ischemia
6.8. Thoracic Radiotherapy and Ischemic Heart Disease

6.8.1. Incidence and Pathophysiology of Radiation-Induced Coronary Artery Disease
6.8.2. Risk Factors for the Development of Ischemic Heart Disease in Radiotherapy Patients
6.8.3. Clinical Assessment and Diagnostic Methods of Coronary Heart Disease in Radiotherapy Patients
6.8.4. Treatment Options in Coronary Artery Disease Associated with Radiotherapy

6.9. Management of Chronic Ischemic Patients Receiving Oncologic Treatment

Module 7. Arrhythmias and Cardiotoxicity

7.1. Incidence and Pathophysiology of Cardiac Arrhythmias Related to Oncologic Treatments
7.2. QT Interval Prolongation: Causative Drugs and Associated Risk Factors
7.3. QT Interval Prolongation: Diagnostic Criteria and Risk Stratification of Ventricular Arrhythmias
7.4. QT Interval Prolongation: Prevention Strategies and Implications on the Continuity of Specific Treatment
7.5. Atrial Fibrillation: Incidence, Risk Factors, and Clinical Presentation
7.6. Atrial Fibrillation: Oncologic Treatments Involved in its Development
7.7. Atrial Fibrillation: Anticoagulant Treatment

7.7.1. Thrombotic and Hemorrhagic Risk Assessment
7.7.2. Anticoagulation with Heparin
7.7.3. Anticoagulation with Dicoumarinics
7.7.4. Direct-Acting Anticoagulants

7.8. Treatment Strategy in Atrial Fibrillation: Rate Control versus Rhythm Control
7.9. Bradyarrhythmias Associated with Oncologic Treatment

7.9.1. Sinus Dysfunction
7.9.2. Atrioventricular Block
7.9.3. Therapeutic Implications

Module 8. Valvular and Pericardial Involvement Related to Cardiotoxicity

8.1. Oncologic Treatments that May Lead to the Development of Valvulopathies

8.1.1. Pharmacological Treatments
8.1.2. Thoracic Radiotherapy

8.2. Management of Chronic Valvular Patients Receiving Oncologic Treatment

8.2.1. Mitral Valve Disease
8.2.2. Aortic Valve Disease
8.2.3. Valve Prosthesis

8.3. Pharmacological Treatments that May Lead to the Development of Pericardial Disease

8.3.1. Incidence and Physiopathology
8.3.2. Clinical Presentation and Diagnosis
8.3.3. Approach to Pericardial Effusion Secondary to Treatment

8.4. Thoracic Radiotherapy and Pericardial Disease

8.4.1. Acute Pericarditis
8.4.2. Chronic Pericarditis

8.5. Assessing Patients with Metastatic Pericardial Involvement

Module 9. Arterial Hypertension as a Result of Oncologic Treatments

9.1. Clinical Relevance of Hypertension in Oncology Patients
9.2. Arterial Hypertension Associated with Antiangiogenic Drugs

9.2.1. Incidence
9.2.2. Pathophysiology
9.2.3. Diagnosis

9.3. Other Treatments Associated with the Development of Arterial Hypertension
9.4. Treatment of Arterial Hypertension Related to Oncologic Treatment
9.5. Monitoring Strategy

Module 10. Venous Thromboembolic Disease and Other Vascular Complications in the Oncology Patient

10.1. Venous Thromboembolic Disease in the Oncologic Patient: Clinical Significance

10.1.1. Incidence
10.1.2. Pathophysiology
10.1.3. Risk Factors

10.2. Antineoplastic Treatments Associated with Increased Risk of Thromboembolic Disease

10.2.1. Chemotherapy and Antiangiogenic Drugs
10.2.2. Hormone Therapy

10.3. Prevention of Cancer-Related Venous Thromboembolic Disease

10.3.1. Prevention Strategy in Outpatients with Active Oncology Treatment. Thrombotic Risk Scales
10.3.2. Prevention Strategy in Hospitalized Patients
10.3.3. Periosurgery Prevention Strategy

10.4. Venous Thromboembolic Disease Related to the Use of Central Venous Catheters

10.4.1. Incidence
10.4.2. Clinical Presentation
10.4.3. Diagnostic Methods
10.4.4. Treatment and Monitoring
10.4.5. Prevention

10.5. Forms of Presentation and Diagnosis of Cancer-Associated Thromboembolic Disease

10.5.1. Deep Vein Thrombosis
10.5.2. Pulmonary Embolism

10.6. Treatment of Cancer-Associated Thromboembolic Disease

10.6.1. Initial Treatment
10.6.2. Extended Treatment

10.7. Management of Thromboembolic Disease in Special Situations

10.7.1. Brain Tumors
10.7.2. Obesity
10.7.3. Renal Insufficiency
10.7.4. Thrombopenia

10.8. Primary Prevention of Cardiovascular Disease in Cancer Patients

10.8.1. Incidence and Risk Factors
10.8.2. Implicated Drugs
10.8.3. Clinical Diagnosis and Treatment

10.9. Cerebrovascular Disease

10.9.1. Incidence and Risk Factors
10.9.2. Implicated Treatments
10.9.3. Clinical Diagnosis and Treatment

10.10. Pulmonary Hypertension

10.10.1. Implicated Drugs Pathophysiology
10.10.2. Clinical Diagnosis
10.10.3. Treatment and Monitoring

Module 11. Therapies with Cardioprotective Effects

11.1. Identification and Control of Cardiotoxicity Risk

11.1.1. Treatment of Traditional Risk Factors
11.1.2. Treatment of Comorbidities

11.2. Strategies to Limit Oncologic Drug-Related Cardiotoxicity

11.2.1. Anthracyclines
11.2.2. Monoclonal Antibodies. HER2 Inhibitors
11.2.3. Cell Kinase Inhibitors

11.3. Strategies to Limit Cardiotoxicity Related to Thoracic Radiotherapy
11.4. Role of Beta-Blockers in Cardioprotection
11.5. Role of Angiotensin Receptor Inhibitors and Antagonists in Cardioprotection
11.6. Other Interventions with a Possible Cardioprotective Effect

Module 12. Long-Term Monitoring Programs for Patients Who Have Received Cardiotoxic Therapies

12.1. Risk of Late Cardiotoxicity Secondary to Oncological Drugs
12.2. Monitoring Protocol for the Detection of Late Cardiotoxicity
12.3. Risk of Late Cardiotoxicity Secondary to Thoracic Radiotherapy
12.4. Monitoring Protocol for Detecting Late Radiation-Induced Toxicity

Module 13. Complex Clinical Situations in the Context of Cardiotoxicity

13.1. Patient with Complex Cardiovascular Disease Requiring Oncologic Treatment
13.2. Patient with Oncologic Disease Presenting with an Acute Ischemic Event
13.3. Pediatric Patients in Need of Potentially Cardiotoxic Oncology Treatment
13.4. Geriatric Patients in need of Oncologic Treatment
13.5. Oncology Patients Requiring Anticoagulation or Anti-Aggregation
13.6. Oncology Patients who Exhibit Arrhythmias and Require Implantable Devices (Pacemakers, Defibrillators)

Module 14. The Future of Cardio-Oncology: Most Relevant Lines of Research

14.1. Basic Research
14.2. Clinical Research
14.3. Gaps in Evidence and Future Research

Module 15. Multidisciplinary Cardio-Oncology Units

15.1. Objectives of the Cardio-Oncology Units

15.1.1. Care Objectives
15.1.2. Research Objectives
15.1.3. Teaching and Dissemination Objectives

15.2. Components of Cardio-Oncology Equipment

15.2.1. Coordination between the In-Hospital and Out-of-Hospital Environment
15.2.2. Coordination between Different Healthcare Professionals

Thoracic Oncology and Advanced Cardio-oncology Area

Module 16. Etiology, Prevention and Screening

16.1. Risk Factors and Prevention

16.1.1. Risk Factors
16.1.2. Lung Cancer and Other Respiratory Diseases (COPD, OSAHS)
16.1.3. Smoking Cessation

16.2. Solitary Pulmonary Nodule

16.2.1. Definition and Etiology. Estimation of Malignancy
16.2.2. Diagnostic Techniques in the Study of Solitary Pulmonary Nodules
16.2.3. Sequential Evaluation. Management Algorithm

16.3. Screening

16.3.1. Screening. Algorithm of Action
16.3.2. Implementation of Screening in the Healthcare System

Module 17. Translational Oncology

17.1. Molecular Biology

17.1.1. Molecular Mechanisms of Cancer
17.1.2. Tumor Immunology: Basis of Cancer Immunotherapy
17.1.3. Microenvironment Reprogramming in Lung Cancer

17.2. Translational Oncology

17.2.1. Understanding the New Technology: Next Generation Sequence (NGS) in Clinical Practice
17.2.2. Therapeutic Targets in NSCLC
17.2.3. Liquid Biopsies in NSCLC: The future is here
17.2.4. Role of the Biobank in Clinical Research

Module 18. Diagnosis and Staging

18.1. Clinical Diagnosis. Serum markers

18.1.1. Clinical Diagnosis
18.1.2. Paraneoplastic Syndromes
18.1.3. Serum markers

18.2. Imaging Techniques

18.2.1. Chest X-ray
18.2.2. Computed Tomography (CT)
18.2.3. Thoracic Ultrasound Scan
18.2.4. Magnetic Resonance Imaging (MRI) in the Assessment of Thoracic Tumors
18.2.5. Positron Emission Tomography (PET)

18.3. Cytohistological Studies

18.3.1. Classification and Anatomopathological Study
18.3.2. Non-Invasive Methods: Sputum Cytology
18.3.3. Bronchoscopic Non-Surgical Invasive Techniques: Standard Bronchoscopy, Ultrasonography (EBUS-EUS), Electromagnetic Navigation and Others
18.3.4. Transthoracic Non-Surgical Invasive Techniques: FNA, CNB, Thoracentesis and Pleural Biopsy
18.3.5. The Role of the Interventional Pathologist in the Diagnosis of Advanced Stage Lung Cancer
18.3.6. Invasive Staging in Lung Cancer

18.4. Functional and Staging Assessment

18.4.1. Preoperative Study of Surgical Risk
18.4.2. The Eighth Edition of TNM Classification of Lung Cancer

Module 19. Basis of Treatment in Thoracic Oncology

19.1. Basis and Experience of Surgical Treatment

19.1.1. Video-Assisted Thoracic Surgery. General Aspects
19.1.2. Robotic Surgery in the Treatment of Lung Cancer and Other Thoracic Tumors
19.1.3. Approach Routes to the Thorax
19.1.4. Lobectomy in the Treatment of Thoracic Tumors. Indications and Technique
19.1.5. Minor Resections in the Treatment of Thoracic Tumors
19.1.6. Pneumonectomy
19.1.7. Bronchoplastic Resections
19.1.8. Angioplastic Resections
19.1.9. Tracheal and Carinal Resection in Lung Cancer and Tracheal Tumors
19.1.10. Lymphadenectomy

19.2. Basis and Experience of Surgical Treatment

19.2.1. Evolution of Radiation Therapy for Thoracic Tumors: from 3D conformal radiotherapy to IMRT/VMAT
19.2.2. Stereotactic Radiotherapy
19.2.3. Pulmonary Brachytherapy
19.2.4. Proton Therapy for Locally Advanced Disease

19.3. Clinical trials in the Era of Personalized Oncology

19.3.1. Clinical Trials: Definitions, Examples, and Interpretation of the Literature
19.3.2. How to Design a Clinical Trial in Lung Cancer
19.3.3. Real World Data Studies: Generating Knowledge

Module 20. Localized and Locally Advanced Stage Non-Small Cell Lung Carcinoma

20.1. Early-stage NSCLC (I-II)

20.1.1. Surgical Algorithm: Technique Selection
20.1.2. Non-surgical Algorithm: Stereotactic Radiotherapy (SBRT)
20.1.3. Current Best Practice for Adjuvant Radiotherapy
20.1.4. Current Best Practice for Adjuvant Chemotherapy

20.2. NSCLC in Advanced Stage (IIIA-IIIB)

20.2.1. Management of Stage IIIA NSCLC
20.2.2. Management of Stage IIIB NSCLC
20.2.3. Radical Radiotherapy in Stage III NSCLC
20.2.4. Concurrent and Sequential Chemotherapy Options in Stage III NSCLC
20.2.5. Toxicity of Radiochemotherapy

20.3. Tumor Pancoast

20.3.1. Diagnosis and Evaluation of Upper Lobe Tumors
20.3.2. Surgical Approach to Sulcus Tumors
20.3.3. Multidisciplinary Management of Upper Lobe Tumors

Module 21. Disseminated Stage Non-Small Cell Lung Carcinoma

21.1. NSCLC in Metastatic Stage. Targeted Therapy in the Treatment of NSCLC

21.1.1. Differentiation between the Treatment of Squamous Carcinoma of Lung A Adenocarcinoma 
21.1.2. Therapeutic Algorithm for NSCLC

21.2. Angiogenic and Targeted Therapy in the Treatment of NSCLC

21.2.1. Angiogenic Therapies in the Management of NSCLC
21.2.2. Targeted Therapy for EGFR-Positive Advanced Disease
21.2.3. Rebiopsy Recommendations After Progression to EGFR-TKIs
21.2.4. Management of EGFR-Resistant Disease
21.2.5. EML4 / ALK, ROS-1: Therapeutic Implications
21.2.6. Mechanisms of Resistance to ALK Inhibitors
21.2.7. Potential and Progress in KRAS, HER2, BRAF, PI3K, MET, TRK and RET Selection
21.2.8. PDL1 Are PDL1 Tests Interchangeable?
21.2.9. Clinical Experience and Current Recommendations for Immunotherapy
21.2.10. Immunotherapy in Patients with PD-L1-Negative NSCLC
21.2.11. Immunotherapy Beyond Immune-Control Inhibitors
21.2.12. The Role of Immunotherapy in Small Cell Lung Cancer and Other Thoracic Tumors
21.2.13. Monitoring and Management of Immune Related Adverse Events

21.3. Oligometastatic Disease

21.3.1. Management of Oligometastatic Disease
21.3.2. Role of Surgery in Oligometastatic Disease
21.3.3. Stereotactic Radiotherapy in Extracranial Oligometastatic Disease
21.3.4. Fractionated Stereotactic Radiotherapy in Oligometastatic Brain Tumors

Module 22. Microcytic Carcinoma of the Lung and Neuroendocrine Tumors

22.1. Microcytic Carcinoma of the Lung

22.1.1. Multidisciplinary Management of Localized Disease
22.1.2. Role of Radiotherapy in Microcytic Lung Carcinoma of the Lung
22.1.3. Management of Disseminated Disease
22.1.4. Prophylactic Cranial Radiotherapy (PCR) in Microcytic Lung Carcinoma of the Lung

22.2. Neuroendocrine Tumors of the Lung

22.2.1. Molecular Biology Approach to Low and Intermediate Grade Neuroendocrine Tumors of the Lung
22.2.2. Clinical Management Algorithm for Bronchial Carcinoid Tumors
22.2.3. Surgical Treatment for Pulmonary Neuroendocrine Tumors

Module 23. Tumors of the Pleura, Mediastinum and Thoracic Wall

23.1. Malignant Mesothelioma

23.1.1. Role of Surgery in Malignant Mesothelioma and Other Pleural Tumors
23.1.2. Role of Radiotherapy in Malignant Mesothelioma
23.1.3. Advanced Malignant Mesothelioma Treatment

23.2. Mediastinal Tumors

23.2.1. Prognostic and Predictive Value of the Pathologic Classification of Thymomas
23.2.2. Role of Surgery in the Treatment of Mediastinal Tumors
23.2.3. Role of Radiotherapy in Thymoma
23.2.4. Multidisciplinary Approach in Advanced Thymoma
23.2.5. New Treatments for Malignant Thymoma

23.3. Thoracic Wall Tumors

23.3.1. Clinic and Diagnosis of Primitive Thoracic Wall Tumors
23.3.2. Surgical Treatment for Primitive Thoracic Wall Tumors

23.4. Treatment of Pulmonary Metastases from Other Tumors

23.4.1. Indications for Surgical Treatment of Pulmonary Metastases from Other Tumors
23.4.2. Surgical Technique in the Treatment of Pulmonary Metastases from Other Tumors
23.4.3. Fractionated Stereotactic Radiotherapy of Pulmonary Metastases from Other Tumors

23.5. Relapses and Second Tumors

23.5.1. Detection of Relapses and Second Tumors
23.5.2. Treatment of Relapses and Second Tumors

Module 24. Collaboration in the Management of Oncology Patients

24.1. Palliative Management

24.1.1. Palliative Care: from Pre-Oncology valoracion to End-of-Life Care
24.1.2. Informed Consent: Are We Really Informing Our Patients?
24.1.3. Palliative Management of Symptoms in Lung Cancer
24.1.4. Palliative Endoscopic Treatments
24.1.5. Palliative Surgical Treatment
24.1.6. Why do Lung Cancer Present to the Emergency Department and How Can Outcomes Be Improved?

24.2. Emergencies and Comorbidities

24.2.1. Palliative Radiotherapy in Brain Metastases, Spinal Cord Compression, Vena Cava Syndrome and Hemoptysis
24.2.2. Acute Management of the Patient with a Thoracic Tumor
24.2.3. Management of Respiratory Comorbidities
24.2.4. Management of Infectious Comorbidities
24.2.5. Management of Cardiovascular Comorbidities
24.2.6. Neurologic Comorbidity Management
24.2.7. Management of Endocrinological Comorbidities
24.2.8. Management of Nutritional Comorbidities
24.2.9. Lung Cancer in the Elderly
24.2.10. Outpatient Care of Patients with Thoracic Oncological Pathology
24.2.11. Prescription of Physical Exercise in the Oncologic Patient. Prehabilitation

Module 25. From Clinical Management to Networking

25.1. Clinical Management in a Thoracic Tumor Unit

25.1.1. Basis of Clinical Management
25.1.2. Members and Functions of a Multidisciplinary Team
25.1.3. Decision-Making in a Multidisciplinary Committee

25.2. Improving Networking

25.2.1. Technological Platforms for Patient Monitoring and Control
25.2.2. The Collaborative On-line World
25.2.3. Decision Support Systems in Oncology Based on Artificial Intelligence
25.2.4. Use of Big Data  in Thoracic Oncology

A unique specialization experience, key and decisive to boost your professional development"